Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Torrent Pharmaceuticals Ltd Performance

Today's Low
2,551.60
arrowIcon
Today's High
2,599.95
52 Wk Low
1,564.55
arrowIcon
52 Wk High
2,744.00


Open

2580

Traded Value (Cr)

34.24 Cr

Prev. Close

2578.95

VWAP

2581.73

Volume

1,75,245

Face Value

5

Torrent Pharmaceuticals Ltd Fundamentals

Market Cap
₹ 87,277 Cr
P/E Ratio (TTM)
60.94
P/B Ratio
13.01
Debt to Equity
0.67
ROE
20.02 %
EPS (TTM)
42.32
Dividend Yield
0.85%
Book Value
198.19

Click here to know more about Fundamentals

Torrent Pharmaceuticals Ltd F&O

Torrent Pharmaceuticals Ltd Option Chain

Torrent Pharmaceuticals Ltd Financials

Torrent Pharmaceuticals Ltd Financials

Torrent Pharmaceuticals Ltd Shareholding Pattern

Held By Dec 2023 Sep 2023 Jun 2023 Mar 2023
Promoters 71.25 % 71.25 % 71.25 % 71.25 %
FII 14.09 % 13.15 % 12.84 % 12.04 %
Others 6.03 % 6.03 % 5.95 % 5.87 %
Mutual Funds 4.48 % 5.32 % 5.59 % 6.37 %
Retail 4.15 % 4.25 % 4.38 % 4.47 %

Promoters

71.25%

FII

14.09%

Others

6.03%

Mutual Funds

4.48%

Retail

4.15%

Promoters

71.25%

FII

13.15%

Others

6.03%

Mutual Funds

5.32%

Retail

4.25%

Promoters

71.25%

FII

12.84%

Others

5.95%

Mutual Funds

5.59%

Retail

4.38%

Promoters

71.25%

FII

12.04%

Others

5.87%

Mutual Funds

6.37%

Retail

4.47%

Resistance and Support

₹2,555.78

PIVOT

resistance-arrow
Resistance
First Resistance₹2,579.567
Second Resistance₹2,599.333
Third Resistance₹2,623.117
support-arrow
Support
First Resistance₹2,536.017
Second Resistance₹2,512.233
Third Resistance₹2,492.467
RSI57.828
MACD-6.622
ADX8.328
CCI-24.083

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day175,24562,83147.30
Week243,967109,36855.85
1 Month295,638166,08755.82
6 Months175,245114,03965.07

About Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Limited, the flagship Company of the Torrent Group, is one of the leading pharmaceutical companies having presence in Indian and global markets. The Company is a dominant player in the therapeutic areas of Cardiovascular (CV), Central Nervous System (CNS), Vitamins and Nutrients (VMN), Gastro-Intestinal (GI) and Anti-Diabetes (AD) therapies in India. It has a strong international presence across more than 40 countries with operations in regulated and emerging markets, such as the US, Europe, Brazil and Rest of the World. The Company operates through its wholly-owned subsidiaries spread across 12 countries with major setups in the US, Germany and Brazil. Apart from this, it has a modern and well-equipped state-of-the-art R&D Centre at Bhat near Ahmedabad, built with an investment of US $ 40 million. Torrent Pharmaceuticals Limited was founded in 1959 as Trinity Laboratories by Late Shri U. N. Mehta. Trinity was later renamed as Torrent Pharmaceuticals Limited and taken public in July 15th, 1972. In 1980, Company started their first manufacturing facility at Vatva and received first export order in year 1983. In year 1986, it started second manufacturing plant at Chhatral. In the year 1995, Torrent Gujarat Biotech Ltd plant was commissioned. In the year 1996, the company acquired the Pharma related investments and business of Torrent Exports Ltd and also commissioned the state-of-the-art R&D centre. In the year 1997, India Infusions Ltd was merged with the company. As a part of restructuring, the company formed three new divisions namely, Prima, Vista and Psycan in the year 1999. During the year 2001-02, the company launched 31 new products, out of which 8 were first time launches in India. The company completed the upgradation and modernization programme for the formulations plant at the total cost of Rs 48 crore. Also, they acquired a small pharmaceutical company, namely Fornex Industrial Farmaceutica Ltda, later renamed as Torrent Do Brasil Ltda, in Brazil for Rs 128 lakh. During the year, the company divested their entire 50% equity stake in Sanofi Torrent (India) Ltd to their joint venture partner Sanofi Synthelabo, France. Also, they transferred their entire equity holding of 1,95,04,691 shares in the sick industrial undertaking Torrent Gujarat Biotech Ltd to Torrent Pvt Ltd, a company belonging to the promoter group. During the year 2002-03, the company introduced 28 new products including the line extensions. The company completed the upgradation of bulk drug plant during the year, which was started during the financial year 2001-02. Also, the company incorporated Torrent Pharma GmbH as a wholly owned subsidiary company in Germany. During the year 2003-04, the company set up a wholly owned subsidiary company, namely Torrent Pharma Inc in USA with the objective of business development in the large, growing and highly profitable North America generic market. Also, they introduced 25 new products during the year. Torrent Pharma's presence in Germany started with the acquisition of Heumann Pharma from Pfizer in 2004-05. The Company entered into a License Agreement with Novartis granting global rights for further development and commercialization of its patented AGE Breaker Compound to Novartis. Also, they signed research collaboration agreement with AstraZeneca, another leading global pharmaceuticals company with the aim of discovering a novel drug candidate for the treatment of hypertension. The company incorporated Torrent Pharma Philippines Inc as a wholly owned subsidiary in the Philippines, with a view to tap the huge potential in Philippines. During the year 2005-06, the company successfully completed capacity expansion and consolidation of bulk drug plant at manufacturing unit in Indrad. The company entered into an agreement with Novo Nordisk India Pvt Ltd, a wholly owned subsidiary of Novo Nordisk A/S, Denmark to extend existing contract manufacturing arrangement for manufacture of Human Insulin formulations. During the year, the company introduced 43 new products in the market. Also, the company launched new divisions AXON and NEURON and expanded their field force in order to tap increasing business opportunities in CNS segment. In April 2006, they launched a new division 'PSYCAN AZUCA' to exclusively cater to the needs of the significant and growing diabetes population in the country. During the year, the company acquired Heumann Pharma GmbH & Co Generica KG (Heumann) of Germany for a cash consideration of euro 3.31 million (Rs.17.20 crores). Heumann, is engaged in the business of marketing generic medicines in Germany under the brand name 'Heumann'. In March 2006, the company incorporated Laboratorios Torrent SA de CV to seek registrations of their products in Mexico and subsequently launch a basket of products in the cardiovascular, central nervous system and oral anti-diabetes area. In April 2006, the company incorporated Torrent Pharma Japan Co Ltd as a wholly owned subsidiary in Japan, to cover the generic market in the country effectively for future business prospects. During the year 2006-07, the company launched 49 new products in the market. The manufacturing facilities at Chatral received approval from the US Food and Drug Administration for the API (active pharmaceutical ingredient) and oral solid dosage formulations facilities. The company initiated process of setting up of a new Greenfield manufacturing site in the state of Sikkim to support the growth in domestic market. Also, the company incorporated a subsidiary in Mexico, named Laboratorios Torrent SA de CV, as a first step for entry into the lucrative Mexican market. During the year 2007-08, the company launched 52 new products in the market. They successfully entered the highly competitive US market with launch of Citalopram. During the year, the company undertook capacity expansion of 30% in tablet formulations at Baddi plant and the project is nearing completion. They also completed development for nine molecules for the European Union market and nine molecules for United States market. During the year 2008-09, the company made an investment of Rs 2.05 crore in the equity shares of their wholly owned subsidiary Laboratories Torrent, SA De CV, in Mexico. In September 2008, the company received the US Food and Drug Administration approval for anti-hypertension drug amlodipine besylate tablets in multiple strengths and in November 2008, their generic, risperidone, in tablet forms of various strengths, also got the approval. In 2009, Torrent Pharmaceuticals commissioned a dedicated formulation and packaging unit for manufacturing insulin exclusively for Novo Nordisk. During the year under review, the company entered into license and supply agreement with AstraZeneca for marketing its products in international market.In 2010, Torrent Pharmaceuticals' Baddi plant received OHAS Audit 18001:2007certification. During the year under review, the Baddi facility was approved by the regulatory authority of Uganda. During the year under review, Torrent Pharmaceuticals forayed into the therapeutic areas of gynaecology and oncology. During the year under review, Torrent Pharmaceuticals commissioned a subsidiary in United Kingdom and Romania. During the year under review, Torrent Research Center developed Long Acting Injectables technology. In 2011, Torrent Pharmaceuticals' Sikkim plant commenced operation. During the year under review, Torrent Research Center developed indigenous Nasal Drug Delivery system. During the year under review, Torrent Pharmaceuticals set up Sparsh, a dedicated division to cater to Dermatology segment. In 2013, Torrent Pharmaceuticals entered into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab. In 2014, Torrent Pharmaceuticals acquired Elder Pharma's identified Indian branded formulation business in India and Nepal. During the year under review, the company launched Nephro, a dedicated division to cater to the Nephrology segment. During the year under review, Torrent Pharmaceuticals' Dahej plant commenced operations. In 2015, Torrent Pharmaceuticals acquired 100% stake of Zyg Pharma, a company engaged in manufacturing various dermatological formulations like creams, ointments, gels, lotions, solutions. In 2016, Torrent Pharmaceuticals' Dahej plant received USFDA approval. During the year under review, the company acquired API manufacturing unit of Hyderabad based Glochem Industries Limited. In 2017, Torrent Pharmaceuticals acquired Unichem's domestic and Nepal business and also its Sikkim manufacturing facility. During the year under review, the company acquired women healthcare brands from Novartis. In 2018, Torrent Pharmaceuticals acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit. As of 31st March, 2019, the Company has 16 subsidiaries, out of which 4 are step down subsidiaries. Bio-Pharm Inc., a wholly owned subsidiary of Torrent Pharma Inc. USA ('TPI') merged with TPI with effect from 1st January, 2019. The merger aims at administrative convenience and to achieve higher operational efficiencies. As of 31st March, 2020, the Company has 15 subsidiaries, out of which 3 are step down subsidiaries. Aptil Pharma Limited, a wholly owned subsidiary of Torrent Pharma (UK) Limited., UK dissolved w.e.f. 15th October, 2019 and consequently, the business of Aptil was merged into Torrent Pharma (UK) Limited. During year 2021, Company launched Dapagliflozin & Rivaroxaban in the Cardiovascular therapy, Brivaracetam in the Central Nervous System therapy, Obeticholic Acid within the Gastro Intestinal therapy and NDDS Tapentadol Nasal spray in Pain Analgesic therapy. During the year 2021-22 , TPL (Malta) Limited, wholly owned subsidiary of the Company and Torrent Pharma (Malta) Limited wholly owned subsidiary of TPL (Malta) Limited were incorporated on 17th August, 2021. During the year 2022-23, the Company acquired 100% of the equity shares of Curatio Health Care (I) Private Limited (CHPL) and its two wholly owned subsidiaries, at Philippines and Sri Lanka for a total consideration costing Rs. 2000 Crores. Accordingly, Curatio Health Care (I) Private Limited (CHPL) was amalgamated with the Parent Company effective from 14th October, 2022, the Appointed Date. The Company launched 6 products in the CNS, diabetic and cardio segments with Rivaroxaban and Desvenlafaxine being the two biggest success.

Managing Director

Founded

1972

NSE Symbol

TORNTPHARM

Torrent Pharmaceuticals Ltd Management

NameDesignation
Sudhir MehtaChairman Emeritus
Samir MehtaExecutive Chairman
Shailesh HaribhaktiIndependent Director
H KhaitanIndependent Director
Ameera ShahIndependent Director
Nayantara BaliIndependent Director
Jinesh ShahDirector (Operation)
Maurice ChagnaudIndependent Director
Aman MehtaWhole Time Director
Manish ChoksiIndependent Director
Chintan TrivediCompany Sec. & Compli. Officer

Torrent Pharmaceuticals Ltd News

Torrent Pharmaceuticals Ltd spurts 0.14%, rises for fifth straight session
Torrent Pharmaceuticals Ltd is quoting at Rs 2574, up 0.14% on the day as on 12:44 IST on the NSE. The stock is up 66.72% in last one year as compared to a 30.72% jump in NIFTY and a 58.98% jump in the Nifty Pharma.
Torrent Pharma Gujarat facility clears USFDA inspection
The drug maker informed that the US drug regulator has issued an establishment inspection report (EIR) for the Bileshwarpura facility in Gujarat stating the inspection to be closed.
Board of Torrent Pharmaceuticals recommends interim dividend
Of Rs 22 per share
Torrent Pharma Q3 PAT jumps 52% YoY to Rs 443 cr
Torrent Pharmaceuticals consolidated net profit surged 51.71% to Rs 443 crore in Q3 FY24 as compared with Rs 292 crore in Q3 FY23.
Torrent Pharmaceuticals consolidated net profit rises 51.71% in the December 2023 quarter
Sales rise 9.43% to Rs 2691.00 crore
Torrent Pharmaceuticals to pay interim dividend
On or around 23 February 2024
Torrent Pharmaceuticals to declare Quarterly Result
On 2 February 2024
Torrent Pharmaceuticals Ltd up for third straight session
Torrent Pharmaceuticals Ltd is quoting at Rs 2265.6, up 1.94% on the day as on 12:49 IST on the NSE. The stock is up 43.24% in last one year as compared to a 18.18% spurt in NIFTY and a 30.28% spurt in the Nifty Pharma index.
Torrent Pharma's Bileshwarpura facility gets Form 483 with 5 observations from US FDA
Torrent Pharmaceuticals said that the US FDA has issued a Form 483 with 5 procedural observations after conducting pre-approval inspection (PAI) at the company’s manufacturing facility based in Gujarat.
Torrent Pharma's oral oncology unit completes USFDA inspection

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,69,497 Cr
₹ 1,540.00
(-3.99 %)
89.67
CIPLA₹ 1,12,773 Cr
₹ 1,396.80
(-1.84 %)
34.28
DRREDDY₹ 1,01,489 Cr
₹ 6,083.85
(-1.20 %)
25.50
DIVISLAB₹ 1,00,339 Cr
₹ 3,779.70
(1.09 %)
73.55
ZYDUSLIFE₹ 96,814 Cr
₹ 962.15
(-3.22 %)
35.99

Torrent Pharmaceuticals Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Torrent Pharmaceuticals Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Torrent Pharmaceuticals Ltd's share price is ₹2,577.70 as of April 12, 2024

Torrent Pharmaceuticals Ltd's P/E ratio is 60.94 times as of April 12, 2024.

Torrent Pharmaceuticals Ltd's most recent financial reports indicate a price-to-book ratio of 13.01, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Torrent Pharmaceuticals Ltd's market is 87,278 Cr as on April 12, 2024.

The current financial records of Torrent Pharmaceuticals Ltd show a 20.02% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Torrent Pharmaceuticals Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Torrent Pharmaceuticals Ltd's 52-week high and low as of April 12, 2024 are ₹2599.95 and ₹2551.6 respectively.

As of the Dec 2023 quarter, the promoter shareholding in Torrent Pharmaceuticals Ltd stands at 71.25%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 13.15% to 14.09%.